[HTML][HTML] PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

H Zhou, J Liu, Y Zhang, Y Huang, J Shen… - NPJ precision …, 2020 - nature.com
H Zhou, J Liu, Y Zhang, Y Huang, J Shen, Y Yang, W Fang, L Zhang
NPJ precision oncology, 2020nature.com
Abstract Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear
cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of
PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to
evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to
immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1
mutation was more likely to be a negative predictive biomarker for immunotherapy in …
Abstract
Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results indicated that PBRM1 mutation was more likely to be a negative predictive biomarker for immunotherapy in NSCLC.
nature.com